Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 1 Baseline demographics

From: Extended-release amphetamine (Dyanavel XR) is associated with reduced immediate-release supplementation in adults with ADHD, regardless of baseline patient variables: a retrospective cohort analysis of medical treatment records

 

Patients

(N = 416)

Age in years, mean (SD)

36.04 (13.47)

Gender, n (%)

 

 Male

135 (32.5%)

 Female

280 (67.3%)

 Non-binary

1 (0.2%)

Race, n (%)

 

 Black

5 (1.2%)

 Asian

1 (0.2%)

 White

399 (95.9%)

 Other

6 (1.6%)

Employment Status, n (%)

 

 College Student

8 (1.9%)

 Employed Full Time

125 (30%)

 Employed Part Time

14 (3.3%)

 Retired

2 (0.5%)

 Disabled

2 (0.4%)

 Student (other)

21 (5.0%)

 Unemployed

10 (2.4%)

 No Data

234 (56.3%)

Marital Status, n (%)

 

 Divorced

9 (2.2%)

 Engaged

5 (1.2%)

 Married

170 (40.9%)

 Partnered

2 (0.5%)

 Separated

2 (0.5%)

 Single

183 (44.0%)

 Widowed

2 (0.5%)

 Missing

43 (10.4%)

Education Completed, n (%)

 

 High school

13 (3.1%)

 Undergraduate

104 (24.7%)

 Graduate

21 (4.0%)

 Middle school

1 (0.2%)

 Some college

27  (12.7%)

 Missing

255 (60.6%)